Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.
Caron A. Jacobson, MD, MMSc, a medical oncologist and medical director of the Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, discusses the design of the phase 2 ZUMA-5 trial (NCT03105336), which evaluated the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory indolent Non-Hodgkin Lymphoma.
According to Jacobson, the study was composed of 2 cohorts. Cohort 1 had an enrollment of 125 patients with follicular lymphoma. Cohort 2 had an aimed enrollment of 35 patients with marginal-zone lymphoma.
All patients included in the study were in their third line of therapy or beyond, meaning the population studied was heavily pretreated, according to Jacobson. The median prior lines of therapy were 3, additionally 70% of patients at the interim analysis had 3 or more prior lines of treatment. According to Jacobson, the population was also high risk. Nearly 50% of patients progressed within the first 2 years after completing front-line therapy.